Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Puma Biotechnology (PBYI) over the last 8 years, with Q4 2024 value amounting to $48.6 million.

  • Puma Biotechnology's Shares Outstanding (Weighted Average) rose 321.29% to $48.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.6 million, marking a year-over-year increase of 321.29%. This contributed to the annual value of $48.6 million for FY2024, which is 321.29% up from last year.
  • As of Q4 2024, Puma Biotechnology's Shares Outstanding (Weighted Average) stood at $48.6 million, which was up 321.29% from $47.1 million recorded in Q4 2023.
  • Puma Biotechnology's Shares Outstanding (Weighted Average)'s 5-year high stood at $48.6 million during Q4 2024, with a 5-year trough of $39.3 million in Q1 2020.
  • For the 5-year period, Puma Biotechnology's Shares Outstanding (Weighted Average) averaged around $42.8 million, with its median value being $40.6 million (2021).
  • In the last 5 years, Puma Biotechnology's Shares Outstanding (Weighted Average) soared by 206.12% in 2020 and then skyrocketed by 993.05% in 2022.
  • Over the past 5 years, Puma Biotechnology's Shares Outstanding (Weighted Average) (Quarter) stood at $39.6 million in 2020, then increased by 2.69% to $40.6 million in 2021, then increased by 9.93% to $44.7 million in 2022, then increased by 5.51% to $47.1 million in 2023, then grew by 3.21% to $48.6 million in 2024.
  • Its last three reported values are $48.6 million in Q4 2024, $47.1 million for Q4 2023, and $44.7 million during Q4 2022.